<div id="readability-page-1"><p>Oscar Health, Inc. (NYSE:OSCR - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $26.06 and last traded at $26.5660, with a volume of 1727899 shares changing hands. The stock had previously closed at $24.51.</p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>5 Small Cap Stocks With Explosive Upside Potential</li></ul><p>A number of research analysts have recently issued reports on OSCR shares. Jefferies Financial Group upgraded Oscar Health from an &#34;underperform&#34; rating to a &#34;hold&#34; rating and lifted their price target for the company from $10.00 to $16.00 in a report on Monday, April 20th. Wall Street Zen downgraded Oscar Health from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Saturday. Raymond James Financial upgraded Oscar Health from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $18.00 target price on the stock in a research note on Thursday, February 12th. Wells Fargo &amp; Company  set a $20.00 target price on shares of Oscar Health and gave the stock an &#34;equal weight&#34; rating in a report on Thursday. Finally, Barclays raised their price target on shares of Oscar Health from $21.00 to $30.00 and gave the company an &#34;equal weight&#34; rating in a report on Tuesday, May 26th. One research analyst  has rated the stock with a Strong Buy rating, two have assigned  a Buy rating, eight have assigned  a Hold rating and one  has issued  a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average price target of $20.22.</p><p><b>Read Our Latest Stock Report on OSCR</b></p><h2>Oscar Health Price Performance</h2><p>The stock has a 50-day moving average price of $18.39 and a two-hundred day moving average price of $16.07. The company has a current ratio of 1.11, a quick ratio of 1.11 and a debt-to-equity ratio of 0.26. The stock has a market cap of $7.92 billion, a price-to-earnings ratio of -44.70, a PEG ratio of 1.71 and a beta of 2.37. </p><p>Oscar Health (NYSE:OSCR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business had revenue of $4.65 billion during the quarter, compared to the consensus estimate of $4.90 billion. During the same quarter last year, the company earned $0.92 earnings per share. The company's quarterly revenue was up 52.6% on a year-over-year basis.  As a group, equities research analysts forecast that  Oscar Health, Inc. will post 0.47 EPS for the current year. </p><h2>Insider Activity</h2><p>In other Oscar Health news, insider Janet Liang sold 12,475 shares of the firm's stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total transaction of $273,701.50. Following the completion of the transaction, the insider directly owned 259,057 shares of the company's stock, valued at approximately $5,683,710.58. This trade represents a 4.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Victoria Baltrus sold 1,523 shares of Oscar Health stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total transaction of $33,414.62. Following the sale, the chief accounting officer owned 214,589 shares of the company's stock, valued at approximately $4,708,082.66. The trade was a 0.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 189,660 shares of company stock valued at $4,283,140. 25.11% of the stock is owned by corporate insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Thrive Capital Management LLC boosted its stake in shares of  Oscar Health by 33.4% in the fourth quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company's stock worth $85,258,000 after buying an additional 1,588,395 shares during the last quarter.  Baird Financial Group Inc. purchased a new position in  Oscar Health during the first quarter valued at approximately $159,000.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in  Oscar Health by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 215,650 shares of the company's stock valued at $2,827,000 after acquiring an additional 8,879 shares during the period.  Jones Financial Companies Lllp boosted its position in  Oscar Health by 7,473.3% in the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company's stock worth $30,000 after purchasing an additional 2,242 shares in the last quarter.  Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in  Oscar Health by 39.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 470,590 shares of the company's stock worth $6,169,000 after purchasing an additional 132,149 shares in the last quarter. 75.70% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Oscar Health</h2> (Get Free Report)<p>Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.  </p><p>The company's primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Oscar Health</li><li>What's Make of Macy's: Berkshire Hathaway's Latest Buy</li><li>Planet Labs: Coming Back Down to Earth</li><li>Docusign: Another Beat, Another Selloff—Why the Analysts Are Wrong</li><li>Meta Unveils Subscriptions: A New Offering With Real Growth Potential</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Oscar Health Right Now?</h2><p>Before you consider Oscar Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oscar Health wasn't on the list.</p><p>While Oscar Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OSCR

OSCG

OSCX

<p>Oscar Health (NYSE:OSCR) reached a new 52-week high of $26.06, driven by recent analyst upgrades and positive earnings surprises. While the company beat EPS estimates with $2.07 per share, revenue fell short of forecasts. Despite insider sales for tax obligations, institutional investors like Thrive Capital increased their stakes. Analysts maintain an average 'Hold' rating with a consensus price target of $20.22.</p>

Oscar Health (NYSE:OSCR) Sets New 52-Week High - Here's Why